secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001787306-25-000096
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis sets director cash retainers at $50k-$35k, annual equity value at $300k; all proposals at annual meeting pass
--------------------------------------------------------------------------------

- Cash retainers: $50k for non-employee directors; additional $35k for non-exec chair; committee chairs $20k (audit), $15k (comp), $10k (nominating).
- Equity: initial option up to $300k value for new directors; annual award ~$300k split 65% option (up to $195k) and 35% RSU (up to $105k).
- Plan amended effective June 11, 2025; board approved revisions to attract and retain qualified directors.
- Shareholders reelected directors Chaudhuri, Lin, Welgus; ratified Ernst & Young as auditor; approved non-binding say-on-pay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000096/0001787306-25-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000096/arqt-20250612.htm
  HTML page:      https://secwatch.observer/filing/0001787306-25-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer